Table 1.
Main characteristics of included cohort studies on COVID-19 in multiple sclerosis
| Study (First author) |
Country | Data lock | Sample size | Deaths | Hospitalization | Confirmed cases* | Mean age |
|---|---|---|---|---|---|---|---|
| Alonso [11] | Latin America | Oct 2020 | 129 | 0 (0%) | 16 (12.4%) | 118 (91.5%) | 41.5 |
| Alshamrani [12] | Saudi Arabia | Feb 2021 | 70 | 0 (0%) | 10 (14.3%) | 70 (100%) | 33.7 |
| Arrambide [13] | Spain | Jun 2020 | 326 | 7 (2.15%) | 79 (24.2%) | 120 (36.8%) | 44.8 |
| Barzegar [14] | Iran | May 2020 | 66 | 1 (1.52%) | 2 (3.0%) | 6 (9.1%) | 37.3 |
| Bayat [15] | Iran | Jun 2020 | 76 | 2 (2.63%) | 12 (15.8%) | 8 (10.5%) | 38.5 |
| Brum [16] | Brazil | Jun 2020 | 94 | 1 (1.06%) | 12 (12.8%) | 22 (23.4%) | 40.6 |
| Bsteh [17] | Austria | Dec 2020 | 126 | 4 (3.17%) | 13 (10.3%) | 126 (100%) | 43.2 |
| Chaudhry [18] | USA | May 2020 | 40 | 4 (10.0%) | 21 (52.5%) | 40 (100%) | 52.8 |
| Ciampi [19] | Chile | Jun 2020 | 14 | 0 (0%) | 5 (35.7%) | 11 (78.6%) | 34.7 |
| Czarnowska [20] | Poland | Apr 2021 | 396 | 1 (0.25%) | 27 (6.8%) | 396 (100%) | 40.1 |
| Loonstra [21] | Netherland | Jun 2020 | 86 | 4 (4.65%) | 22 (25.6%) | 43 (50.0%) | 45.5 |
| Louapre [22] | France | May 2020 | 347 | 12 (3.46%) | 73 (21.0%) | 146 (42.1%) | 44.6 |
| Parrotta [23] | USA | Apr 2020 | 72 | 5 (6.94%) | 15 (20.8%) | 35 (48.6%) | 44.9 |
| Sahraian [24] | Iran | May 2020 | 68 | 2 (2.94%) | 17 (25.0%) | 68 (100%) | 37.3 |
| Salter [25] | North America | Dec 2020 | 1626 | 49 (3.01%) | 320 (19.7%) | 1,345 (82.7%) | 47.7 |
| Sen [26] | Turkey | Sep 2020 | 309 | 3 (0.97%) | 94 (30.4%) | 291 (94.2%) | 36.9 |
| Sormani [27] | Italy | Sep 2020 | 844 | 13 (1.54%) | 96 (11.4%) | 279 (33.1%) | 45.0 |
| Stastna [28] | Czechia | Feb 2021 | 945 | 3 (0.32%) | 39 (4.1%) | 844 (89.3%) | 43.5 |
| Pooled | – | – | 5634 | 111 (1.97%) | 873 (15.5%) | 3968 (70.4%) | 41.8 |
*By positive reverse transcriptase polymerase chain reaction (RT-PCR) on nasal and/or pharyngeal swabs